NEW SILICON PHTHALOCYANINE COMPOUNDS WITH HIGH POTENTIAL AS IN VITRO BIOLOGICALLY ACTIVE DRUG CANDIDATES FOR THE TREATMENT OF TYPE 2 DIABETES.

Abstract

This invention relates to silicon phthalocyanine compounds containing (4-(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy and (3,5-bis(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy) groups in axial positions, which have high potential as drug candidates for the treatment of type 2 diabetes, are easily synthesized, low-cost, and have more effective α-glucosidase inhibition activity than α-amylase, and the synthesis method of these compounds.

Description

1 TARIFF A drug with in vitro biological activity for the treatment of type 2 diabetes. NEW SILICON PHTHALOCYANINE COMPOUNDS WITH HIGH POTENTIAL TO BECOME CANDIDATES Technical Area The invention addresses a disease that is increasing in number worldwide each year, can be fatal, and requires 5 years of treatment. activity for the treatment of type 2 diabetes, a metabolic disease requiring high costs Compared to compounds used in type 2 diabetes, it has higher toxicity and lower side effects. reduced effects, (4-(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy and (3,5-bis(3-(3- Silicon phthalocyanine compounds containing (morpholinophenoxy)propoxy)phenyl)methoxy groups and these It is concerned with providing the pharmaceutical industry with new drugs through the synthesis of compounds. 10 State of the Art Diabetes, a chronic metabolic disorder, is characterized by impaired carbohydrate, lipid, and protein metabolism. It is characterized by impaired insulin signaling, retinopathy, nephropathy, cardiovascular diseases, and others. This results in illnesses. Diabetes, according to case numbers, is generally classified as type 1 (T1D) and type 2 (T2D) diabetes. They are grouped into two categories. T1D is a 15-year-old pancreatic beta-cell disorder resulting from autoimmune destruction of pancreatic beta cells. It manifests itself as low levels of insulin secretion. T2D is also known as insulin-dependent insulin. It is also called diabetes and mostly affects younger ages, including teenagers and even children. It affects people in certain groups. The cause of T1D is mostly genetic and therefore inherently high. It is largely hereditary. In contrast, T2D is associated with hyperglycemia, insulin resistance, or defects in insulin action. It is a progressive and multifactorial disease characterized by relative insulin deficiency. From T2D to 20 Individuals suffering from atherosclerosis, dyslipidemia, fatty liver, hyperlipidemia, stroke, cardiovascular disease the disease can lead to various complications including blindness, nephropathy, diabetic neuropathy, etc. It is possible. T2D is also known as non-insulin-dependent diabetes or adult-onset diabetes. It is the most prevalent type of diabetes, affecting approximately 90-95% of people. International Diabetes According to the latest global estimate by the International Diabetes Federation (IDF) (2017), 425 million people have diabetes. This means that one in ten adults is affected by the disease. (IDF 2021) According to 2010 estimates, the number of patients is expected to reach 629 million by 2045. This estimate... By 2045, 1 in 8 adults will have diabetes. Adults living with diabetes... It is estimated that 44.7% (240 million people) remain undiagnosed. In the treatment of T2D, 30 days are needed to achieve and maintain normal blood sugar levels. This requires the use of antidiabetic agents. Treatments include increasing insulin secretion. Sulfonylureas and repaglinide, troglitazone to increase insulin activity, insulin in the liver metformin to improve its mechanisms and miglitol to reduce the rapid absorption of carbohydrates. Acarbose is present. It is produced in the small intestine by α-glucosidase, as well as in the salivary glands and pancreas. The α-amylase found plays an important role in postprandial blood glucose. The activity of these enzymes is 35 Inhibition of α-glucosidase can slow down the hydrolysis of carbohydrates and the release of glucose. Therefore, α-glucosidase and α-amylase has become a therapeutic target for the prevention and management of T2D. 2 However, most of the drugs currently prescribed inhibit the α-glucosidase and α-amylase enzymes. Over time, it loses its effectiveness, becomes expensive, has side effects, and interacts with other drugs. Acarbose, miglitol, and voglibose are commonly used to inhibit α-glucosidase and α-amylase. Used but can cause gas, weight gain, nausea, urinary tract infections, abdominal discomfort, diarrhea, kidney problems. These are medications that have many side effects, such as tumors and liver damage. Therefore, those who suffer from diabetes for a long time... The person experiencing this condition experiences adverse effects in certain parts of their body. These unwanted side effects... Therefore, the development of alternative medicines continues. We are able to overcome all these problems. For this, a new metal-based α- has high therapeutic potential but low side effects. A great deal of effort is being devoted to the development of new drugs that are glucosidase and α-amylase inhibitors. For the development of these new types of drugs, phthalocyanines represent a major advantage in terms of both synthesis and application. They have potential. Phthalocyanines, which have an 18π-electron system, are similar in structure to porphyrins. Unlike imine bridges and pyrrole rings, it has isoindole bridges and isoindole rings. This structural feature... Due to these differences, phthalocyanines exhibit intense absorption at ~700 nm and therefore in the infrared range. It is considered one of the elite classes of light-absorbing organic compounds. Visible, red, and NIR light. Despite their interesting optical properties in this region, the applications of these hydrophobic planar molecules are weak. 15 Due to their resolutions and aggregate formation tendencies, it could not be fully realized. Planarity and to reduce the degree of hydrophobicity, suitable aromatic substitutions or the addition of an element to the core structure Solubility was increased, clumping was reduced, and simple structural changes such as the inclusion of additional elements were made. Easy synthetic pathways have been developed. Among these compounds, silicon phthalocyanines are unusual. It has attracted attention thanks to the remarkable chemical stability of hexacoordinated silicon (IV) and Si‒N bonds. 20 Furthermore, the presence of two unique axial locations that can be easily functionalized with selected ligands makes it very versatile. This makes it unique among numerous phthalocyanines. Furthermore, the bulky or polar groups in axial positions. α or β substitutions reduce aggregation and increase resolution while disrupting planarity. It is more effective than phthalocyanines. Remarkably, axial Si‒O and Si‒C bonds are used in medical biology. Its unique properties, combined with low synthesis cost and low toxicity, lead to fascinating applications. and has led to consequences, particularly in biological studies involving peripheral and non-peripheral metals. In comparison to phthalocyanines, silicon phthalocyanines are superior thanks to the presence of axial ligands. By increasing the distance between phthalocyanine rings, it prevents interring interaction. Potential enzymes can be used to achieve more effective results in biological studies by reducing aggregation. Its potential use as an inhibitory agent in the treatment of metabolic diseases is of significant importance. 30 In the known state of the art, in patent application CN108129522A, phthalocyanine aryl ruthenium preparation of the compound and its high α-glucosidase enzyme inhibition activity in diabetes He explains that this would be a good practice in the treatment of the disease. Another patent application, numbered CN117250248A, describes metalliftalocyanonine and a metal organic scaffold (MOF). Preparation of modified graphene-based hybrid gas detection systems and their reliable operation 35 The text discusses the effective differentiation between individuals with diabetes and those who are not. Another patent application, numbered CN111481605A, describes a foot implant for treating diabetic foot. The bath and the method and application of its preparation are described. This invention provides... The foot bath solution contains approximately 4% different metal phthalocyanine compounds and is suitable for diabetics. It is reported to have a good effect in the treatment of feet. 40 3 In another patent application, numbered WO2012103382A2, sulfated reactive copper and zinc are described. A device made with phthalocyanine-based antimicrobial textile fabric can detect diabetes. It mentions that it can be used for this purpose. Patent application number WO2000009111 describes metabolic diseases such as type 2 diabetes, and especially prion 5 associated with the conversion of protease-sensitive PrP (PrP-sen) to protease-resistant PrP (PrP-res). Methods for treating their diseases by administering therapeutically effective amounts of tetrapyrrole, Compounds and compositions have been described. Among the specifically described tetrapyrroles possessing this activity are: It is stated that phthalocyanines, deuteroporpyrins, and meso-substituted porphines are present. Considering the explanations and patents mentioned above, diabetes is a major concern today. Besides the shortcomings and disadvantages in the techniques used to treat the disease, there are also inadequacies. 10 Keeping it is a necessity in the research of new, simple and effective methods and a development in the relevant field. This makes it necessary to do it. Purpose of the Invention One of the major health problems of our time is the presence of various drugs with side effects, 15 Despite the development of treatments, a definitive cure has not yet been found for diabetes, resulting in a high mortality rate. It is increasing every year. The death rate from diabetes reached 6.7 million adults in 2021, which is one in every 5 That means one death per second. The aim of this invention is to develop acarbose, miglitol, and other compounds commonly used in the treatment of type 2 diabetes. Compared to drugs like voglibose, it has fewer side effects, is easy to synthesize, is inexpensive, and its effect is as described above 20 years ago. (4-(3-(3-morpholinphenoxy)propoxy)phenyl)methoxy and (3,5-bis(3-(3- Synthesis of silicon phthalocyanine compounds containing morpholinphenoxy)propoxy)phenyl)methoxy groups and its use in the treatment of type 2 diabetes. Another aim of the invention is to investigate, in in vitro studies, the correlation between α-glucosidase and α-amylase enzymes. The reason is that it will show higher activity when compared. Thus, α-glucosidase activity is higher than α-25 High amylase inhibition activity affects bacterial fermentation throughout the gastrointestinal tract. This paves the way for the development of candidate drugs with fewer side effects by preventing starch accumulation. It has been opened. Another aim of the invention is to investigate the preclinical efficacy of these compounds, which have high potential to become pharmaceuticals. It is developed through in vitro, in vivo and toxicological studies. With these synthesized drug candidates, type 2 diabetes 30 In addition to reducing the high costs caused by the treatment of the disease, it also reduces dependence on foreign countries. This will prevent further complications. Furthermore, it will enable the application of promising new treatment methods. In addition to providing assurance, effective results will be obtained. Explanation of Figures 35 The invention summarized above can be more easily explained by referring to the figures and descriptions summarized below. understandable. Figure 1. Lineweaver-Burk plot for compound #1 for α-glucosidase enzyme. Figure 2. Lineweaver-Burk plot of compound number 2 for α-glucosidase enzyme. 4 Description of the Invention The invention relates to (4-(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy and (3,5-bis(3-(3- Silicon phthalocyanine compounds containing (morpholinophenoxy)propoxy)phenyl)methoxy groups, these It is concerned with the synthesis methods of compounds and the investigation of their in vitro biological activities. 5 synthesized Compound coded Bis(4-(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyanine silicon (IV) 5 Formula III and code 7 Bis(3,5-bis(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyanine The silicon (IV) compound is represented by the formula V. The structures of the synthesized compounds were determined using FT-IR, NMR, UV-Vis and It has been characterized using MS techniques. The synthesis of silicon phthalocyanine compound coded 5, shown in formula III, whose biological activity was investigated, was carried out in three stages. It consists of 10 stages. Step 1: The compound 4-(3-(3-chloropropoxy)phenyl)morpholine, coded 3 in Formula I synthesis,  1 g (5.6 mmol) of 3-morpholinephenol compound and 200 mg (8.4 mmol) of NaH compound were added to a single-necked flask. by adding and dissolving in DMF (N,N-dimethylformamide),  Slowly add 0.6 mL (5.6 mmol) of 1-bromo-3-chloropropane to the dissolved mixture and bring to room temperature. Mixing under these conditions for 1 day,  After the reaction, the mixture is poured into ice water and stirred.  Next, CHCl3 is added to the mixture and stirred for 6 hours, followed by a water:chloroform mixture of 20... extraction by,  Evaporation of the solvent from the resulting organic phase,  The obtained crude product is loaded onto a column loaded with aluminum oxide and purified with chloroform. to be done  By collecting and combining the fractions and removing the solvent by evaporation 25 The resulting product is dried in a vacuum desiccator. Below is the formula coded 3-4-(3-(3-) shown in I, which was synthesized as a result of Stage 1. The synthesis scheme of the compound (chloropropoxy)phenyl)morpholine is shown. Step 2: The compound coded 4 (4-(3-(3-morpholinephenoxy)propoxy)phenyl)methanol) shown in Formula II synthesis,  600 mg of 4-(3-(3-5) coded 3 (2.35 mmol) shown in formula I, synthesized in step 1. 291 mg (2.35 mmol) of chloropropoxy)phenyl)morpholine compound in a single-necked flask 1.24 g (4.7 mmol) of hydroxybenzyl alcohol in acetone in the presence of 2.37 g (17.2 mmol) of K2CO3 Mixing of 18-crown-6 at 70 °C for 2 days under a nitrogen atmosphere,  After the reaction, the mixture is cooled to room temperature and filtered through black tape filter paper. filtering, 10  Evaporation and removal of the obtained organic phase and aluminum oxide-loaded raw product Purification process with CHCl3 in the column,  Evaporation of the solvent to collect the fractions and vacuum processing of the resulting crude product drying in a desiccator, Below is the formula obtained as a result of Stage 2, shown in section II with code 4 (4-(3-(3-15 The synthesis scheme of the compound morpholinephenoxy)propoxy)phenyl)methanol is shown. Step 3: Bis(4-(3-(3- 5 code shown in Formula III 6 Synthesis of the compound morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyanine silicon (IV),  125 mg (0.36 mmol) of the compound coded 4 (4-(3-(3-) shown in formula II, synthesized in step 2. 100 mg (0.164 mmol) of morpholinephenoxy)propoxy)phenyl)methanol compound containing dichlorosilicon Dissolving phthalocyanine compound in toluene, 5  Adding 1 spatula tip of NaH to the reaction mixture and degassing the dissolved oxygen in the system. by removing  Then the reaction mixture is stirred for 1 day at 110 °C in a nitrogen atmosphere,  Removing the solvent from the mixture by evaporation after it has cooled to room temperature,  The purification process of the obtained crude product with CHCl3 in an aluminum oxide-loaded column is 10 to be done,  The fractions are combined, the solvent is removed, and the resulting product is placed in a vacuum desiccator. drying, Below is the formula obtained as a result of Stage 3, shown in III with code 5: Bis(4-(3-(3- Synthesis scheme of the compound morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyanine silicon (IV) 15 It has been shown. 7 Another silicon phthalocyanine compound whose biological activity is being investigated is Bis(3,5-bis(3-(3- morpholinophenoxy)propoxy)phenyl)methoxy) phthalocyanine silicon (IV) compound with formula V It has been shown. The synthesis of silicon phthalocyanine compound coded 7, shown in formula V, consists of two steps. 5 Step 1: Code 6 (3,5-bis(3-(3-morpholinephenoxy)propoxy)phenyl)methanol shown in Formula IV synthesis of the compound,  675 mg (2.63 mmol) of 4-(3-(3-) coded 3 (2.35 mmol) as shown in formula I was injected into a single-necked flask. The compound chloropropoxy)phenyl)morpholine is dissolved in 30 mL of acetone, 10  175 mg (1.25 mmol) 3,5-dihydroxybenzyl alcohol and 2.57 g (18.25 mmol) dry oil were added to the reaction mixture. Addition of K2CO3 and 528 mg (2 mmol) of 18-crown-6,  After degassing the reaction mixture, stirring it in a nitrogen atmosphere at 70°C for 2 days.  After the reaction, the mixture is cooled to room temperature and filtered through black tape filter paper. filtration and evaporation of the organic phase, 15  Purification of the obtained crude product using chloroform through an aluminum oxide-loaded column, 8  The collected fractions are combined, the organic phase is removed by evaporation, and the resulting fraction is obtained. drying the product in a vacuum desiccator, Below is the compound coded 6 (3,5-bis(3-(3-morpholinphenoxy)propoxy)phenyl)methanol shown in formula IV. The synthesis diagram is shown. Step 2: Bis(3,5-bis(3-(3- 7 code shown in Formula V Synthesis of the compound morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyaninato silicon (IV),  100 mg (0.164 mmol) dichlorosilicon phthalocyanine and 200 mg (0.34 mmol) in a single-necked balloon 9 mmol) shown in formula IV, code 6 (3,5-bis(3-(3-morpholinphenoxy)propoxy)phenyl)methanol the compound is dissolved in 10 mL of dry toluene,  Adding 1 spatula tip of NaH to the reaction mixture and degassing the dissolved oxygen in the environment by removing  Then, the reaction mixture is stirred for 1 day at 110 °C under a nitrogen atmosphere, 5  Removing the solvent from the mixture by evaporation after it has cooled to room temperature,  The obtained crude product is placed in a silicon oxide loaded column using a chloroform:methanol (250:3) solvent system. purification process carried out with,  The fractions are combined, the solvent is removed, and the resulting product is placed in a vacuum desiccator. drying, 10 Below is the code 7 Bis(3,5-bis(3-(3- ) obtained as a result of Stage 2 and shown in formula V. Synthesis scheme of the morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyaninato silicon (IV) compound It has been shown. BIOLOGICAL ACTIVITY STUDIES Enzyme inhibition of silicon phthalocyanine compounds coded 5 and 7, shown in Formulas III and V respectively. The activities were performed triplicate using the UV-Vis spectrophotometric method, and the results were presented. This information has been shared. Table 1 shows that, according to the results obtained, silicon phthalocyanine compounds are effective against α-glucosidase. While showing inhibitory activity, it showed low α-amylase enzyme inhibitory activity. This situation 20 Because it will prevent starch accumulation for bacterial fermentation throughout the gastrointestinal system, it is low. α-Amylase enzyme activity, rather than being a disadvantage, leads to a reduction in side effects. The synthesized compounds represent innovative treatment methods in the treatment of type 2 diabetes. It makes a difference. Enzyme Inhibition Experiments 5 In vitro α-glucosidase enzyme inhibition studies Stock solutions of silicon phthalocyanine compounds coded 5 and 7, shown in Formulas III and V, contain 2 of the compounds. It was prepared by dissolving it in 500 µM dimethyl sulfoxide and then diluting it with distilled water to a concentration of 500 µM. These solutions were then used in the study. Acarbose was used as the standard inhibitor. 96 100 µL of α-glucosidase (0.5 U / mL) enzyme in a well plate was mixed with silicon 10⁻¹⁰ prepared at different concentrations. to the compounds and also in 50 µL of 0.1 M phosphate buffer (pH = 6.9) at different concentrations (12.5-100 (µM) acarbose was added. The mixtures were then incubated at room temperature for 10 minutes. Then, 50 µL of p-nitrophenyl-α-D-glucopyranoside (4-pNPG) (5 mM) solution was added as substrate and It was incubated at room temperature for 10 minutes. Absorbance was measured at 405 nm using a microplate reader. The detected inhibition rates are given in Table 1 below. 15 In vitro α-amylase enzyme inhibition studies Acarbose was used as the standard inhibitor. In a 96-well plate, 10 µL of α-amylase (50 U / mL) enzyme was added. silicon phthalocyanine compounds prepared at different concentrations and 50 µL of 100 mM phosphate buffer (pH = 6.8) acarbose was added at different concentrations (12.5-100 µM). Then 20 The mixtures were incubated at room temperature for 20 minutes. Then, 150 µL of 1% starch was added as substrate. The solution was added and incubated at room temperature for 20 minutes. Then, 20 µL of 3,5-dinitrosalicylic acid was added. The acid (DNSA) reagent, potassium sodium tartrate, and finally 20 µL of 2 N NaOH were added to the thermostat. The mixture was incubated in a shaker at 100°C for 20 minutes. Absorbance was measured using a microplate reader as 540. It was detected at nm and the inhibition rate is given in Table 1 below. 25 Table 1. Inhibition of α-Glucosidase and α-Amylase Enzymes by Silicon Phthalocyanine Compounds Coded 5 and 7. activities Compounds α-Glucosidase (μM) α-Amylase (μM) 16.02 ± 0.94*** >100 7 44.14 ± 4.06*** >100 Acarbose 60.51 ± 4.66 25.29 ± 3.50 Kinetic Analysis of Compounds 30 Kinetic analyses of silicon phthalocyanine compounds coded 5 and 7 shown in Formulas III and V. When examined, it was determined that it had the highest effect on the α-glucosidase enzyme. 11 The type of inhibition and the Ki value were determined using a Lineweaver-Burk plot. In the plot, the Km value is X. The corresponding value on the axis is determined by (1 / [S]) and the Vmax value is the corresponding value on the Y-axis. Determined by (1 / V). For both compounds, the enzyme concentration was kept constant at 0.5 U / mL in the study, and at 2.5, 5, 10, and 20 mM. The substrates used were: silicon 5 with code 5, shown in Formula III as the calculated IC₅₀ values. For phthalocyanine, 6.02 µM and for silicon phthalocyanine coded 7 in formula V, 44.14 µM were studied. The types of α-glucosidase enzyme inhibition and Ki values ​​of the compounds are then given in Table 2. Table 2. α-Glycosidase enzyme inhibition types and Ki of silicon phthalocyanine compounds coded 5 and 7. values ​​10 Compound Inhibition type Ki (μM) non-competitive 9.45 ± 1.45 7 non-competitive 29.06 5.16 How the invention can be applied to industry. This invention will provide the necessary collaboration between pharmaceutical companies developing drugs for the treatment of type 2 diabetes. Discussions will be held and these drug candidates will be synthesized in drug form. The synthesized drugs T2D disease is treated by administering tablets orally or intravenously dissolved in liquid. It will be administered via this route and used in the treatment of patients. Thus, it has low side effects. effective results that do not leave long-term negative effects on patients and are promising for patients. These measures will be taken. As a result, the number of people suffering from type 2 diabetes is steadily increasing. The costs of treating this disease and the budgets allocated by governments for this disease will decrease. The amounts will decrease. Furthermore, this will open doors to new employment and business opportunities for relevant entrepreneurs in this field. It will open.

Claims

12 REQUESTS 1. It is a drug that can be injected directly into the body; its characteristic feature is that its formula III compound is a single chemical component. It has.

2. According to claim 1, the compound formula III is Bis(4-(3-(3- The molecule has the name morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyanine silicon (IV). Silicon phthalocyanine containing (4-(3-(3-morpholinophenoxy)propoxy)phenyl)methoxy) groups It is a compound.

3. A method for producing compound formula III according to claim 1, the characteristic of which is; the following steps 10 Includes:  The starting compound, 3-morpholinephenol, is mixed with 1-bromo-3-chloropropane using NaH and DMF. reacting it under suitable conditions in its presence,  Pouring the reaction mixture onto ice and performing extraction with chloroform / water,  The organic phase separated after extraction is dried with MgSO4 and the solvent is evaporated with a 15 removal,  The obtained crude product is processed with chloroform through a column loaded with appropriate aluminum oxide, after checking its TLC. purification,  The fractions taken from the column are collected, the solvent is evaporated and 4-(3-(3- Synthesis of the compound chloropropoxy)phenyl)morpholine, 20 13  The resulting 4-(3-(3-chloropropoxy)phenyl)morpholine compound is mixed with 4-hydroxybenzyl alcohol. Reaction of K2CO3 in the presence of acetone and 18-crown-6 under appropriate conditions,  Cooling the reaction mixture to room temperature and filtering it through black tape filter paper. and evaporation of the organic phase,  Purification of the obtained crude product with chloroform through an aluminum oxide-loaded column, 5  Combining the fractions taken from the column to remove the solvent and (4-(3-(3- Synthesis of the compound morpfolinphenoxy)propoxy)phenyl)methanol,  The resulting (4-(3-(3-morpholinphenoxy)propoxy)phenyl)methanol compound contains dichlorosilicon Reaction of phthalocyanine with NaH and toluene under appropriate conditions,  After the reaction, the mixture should be cooled to room temperature and the solvent should be evaporated. 10  Purification of the obtained crude product with chloroform through an aluminum oxide-loaded column,  Combining the obtained fractions, evaporating the solvent, and Bis(4-(3-(3- morpholinophenoxy)propoxy)phenyl)methoxy)phthalocyanineato silicon (IV) synthesis, 4. According to claim 1, compound III has high α-glucosidase enzyme inhibition activity in type 2 diabetes. 15 It is aimed at treating the disease.

5. According to Claim 1, another compound that can be directly injected into the body is characterized by having a single compound with the formula V. It has a chemical component. 14 6. According to claim 1, the compound with the formula V is Bis(3,5-bis(3-(3-morphylphenoxy)propoxy)phenyl)methoxy) phthalocyanine silicon (IV) molecule with the name 3,5-bis(3-(3- It is a silicon phthalocyanine compound containing morphylphenoxy)propoxy)phenyl)methoxy groups.

7. A method for producing compound V according to claim 4, and its characteristic is; the following steps Includes: 5  4-(3-(3-chloropropoxy)phenyl)morpholine compound and 3,5-dihydroxybenzyl alcohol K2CO3 and 18- Reaction of crown-6 in acetone in the presence of,  At the end of the reaction, the mixture is filtered through black band filter paper and the organic phase is separated. removal by evaporation,  Purification of the obtained crude product with chloroform through an aluminum oxide-loaded column, 10  Combining the collected fractions, evaporating the solvent, and (3,5-bis(3-(3- Preparation of the compound morpholinephenoxy)propoxy)phenyl)methanol,  (3,5-bis(3-(3-morpholinphenoxy)propoxy)phenyl)methanol compound with NaH and toluene reacting in the presence of,  Evaporation of the mixture after it has cooled to room temperature to remove the solvent, 15  Purification of the obtained crude product with chloroform through an aluminum oxide-loaded column,  By combining the collected fractions and evaporating the solvent, Bis(3,5-bis(3-(3- morpholinophenoxy)propoxy)phenyl)methoxy) phthalocyanine silicon (IV) compound obtaining, 8. According to claim 5, compound V has high α-glucosidase enzyme inhibition activity in type 2 diabetes 20 It is aimed at the treatment of the disease.

Images